Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Corcept Therapeutics Incorporated

CORT
Current price
22.95 USD +0.35 USD (+1.55%)
Last closed 22.66 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 441 207 808 USD
Yield for 12 month +2.91 %
1Y
3Y
5Y
10Y
15Y
CORT
21.11.2021 - 28.11.2021

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California. Address: 149 Commonwealth Drive, Menlo Park, CA, United States, 94025

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

42.8 USD

P/E ratio

25.0106

Dividend Yield

Current Year

+482 375 000 USD

Last Year

+401 858 000 USD

Current Quarter

+135 405 000 USD

Last Quarter

+123 601 000 USD

Current Year

+475 894 000 USD

Last Year

+396 473 000 USD

Current Quarter

+133 528 000 USD

Last Quarter

+121 956 000 USD

Key Figures CORT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 108 324 000 USD
Operating Margin TTM 23.39 %
PE Ratio 25.0106
Return On Assets TTM 11.13 %
PEG Ratio 0.61
Return On Equity TTM 21.05 %
Wall Street Target Price 42.8 USD
Revenue TTM 482 375 008 USD
Book Value 4.9 USD
Revenue Per Share TTM 4.66 USD
Dividend Share
Quarterly Revenue Growth YOY 31.4 %
Dividend Yield
Gross Profit TTM 396 473 000 USD
Earnings Share 0.94 USD
Diluted Eps TTM 0.94 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY 99.5 %
Profit Margin 22 %

Dividend Analytics CORT

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CORT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CORT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 25.0106
Forward PE 71.4286
Enterprise Value Revenue 4.2956
Price Sales TTM 5.0608
Enterprise Value EBITDA 18.8985
Price Book MRQ 4.8158

Financials CORT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CORT

For 52 weeks

20.87 USD 34.28 USD
50 Day MA 23.75 USD
Shares Short Prior Month 20 215 345
200 Day MA 26.54 USD
Short Ratio 23.77
Shares Short 21 330 479
Short Percent 33.11 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics